Co-administration of Dexmedetomidine in Carotid Endarterectomy (CEA)
Status:
Completed
Trial end date:
2020-12-04
Target enrollment:
Participant gender:
Summary
All neurosurgical patients at the Neurosurgery University Hospital Bern who will be operated
for carotid endarterectomy (CEA) are routinely operated in deep anae¬sthesia with suppression
of the electrical activity of the electroencephalogram (EEG). To achieve this suppression of
the EEG activity (burst suppression, BS) high effector concentrations (Cet) of Propofol doses
are needed. However, a protracted infusion of large amounts of Propofol to reach a BS during
the operation can lead to accumulation and a protracted wake-up phase with poorer
neurological assessability. Somatosensory evoked potentials (SSEP), and trans-cranial Doppler
flow velocity in the middle cerebral artery are measured to detect ischemia until the
operation. The SSEPs are used to verify the functional integrity of the nervous system in
combination of the EEG and both together exclude severe global ischemia during the operation.
The central acting α2-agonist Dexmedetomidine could help to reduce the amount of Propofol
without influencing electrophysical studies. However, no data are currently known for
practical use in carotid endarterectomy with Propofol with co-administration of
Dexmedetomidine in conjunction with electrophysiological studies (SSEPs and MEPs).